Southeastern Clinical Research Institute, LLC (SCRI) is an Independent Clinical Research Institute incorporated in 2005.
Located in Augusta, Georgia, we specialize in conducting clinical trials for patients dealing with various types of kidney disease. We are always discussing and reviewing new clinical trials to bring to our patient population. Having participated in over 100 clinical trials, we actively participate in bringing novel, life-changing medications to market.
Southeastern Clinical Research Institute has conducted phase IB-IV clinical trials since 2005 in the following therapeutic areas
Chronic Kidney Disease
Cardiovascular Disease
Anemia
Diabetes Mellitus
Dialysis Access
Hyperparathyroidism
Hyperphosphatemia
Hypertension
Iron Deficiency
Glomerulonephritis
Proteinuria
Hyperlipidemia
Kidney Disease
Immunology
Polycystic kidney disease
Lupus Nephritis
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Actively Enrolling Clinical Trials
AZ Baxdrostat
/in Clinical TrialsThe primary objective of this study is to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Calliditas Therapeutics AB
/in Clinical TrialsThe goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice.
Bayer: 22040
/in Clinical TrialsThis study will evaluate the safety and efficacy of study drug, BAY3283142, in combination with standard of care (SoC), in the treatment of albuminuria in adult chronic kidney disease (CKD) patients.
Eli Lilly and Company: J1I-MC-GZBO
/in Clinical TrialsThe main goal of this study is to evaluate the effect of retatrutide on cardiovascular and kidney outcomes in adults living with obesity.
Eli Lilly and Company: J3L-MC-EZEF
/in Clinical TrialsThe main purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.